Among midlife women, only about 21% reached ideal cardiovascular health scores at baseline, per the American Heart ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

AngioDynamics (Nasdaq:ANGO) announced today that it enrolled the first patient in a randomized study of its Auryon ...

On July 15, CMS issued its proposed rule for its 2026 physician fee schedule, that included a 3.6% bump to physician payments. The overall reimbursement for cardiovascular services is projected to ...

AngioDynamics, Inc. announced enrollment of the first patient in the AMBITION BTK study of the Auryon atherectomy system.

A joint SCCT/SCAI panel reviewed many opportunities for CT to enhance procedural planning and foster multidisciplinary care.

Five Dogs of the Dow stocks are not only higher on the year but still offer big yields, a degree of safety from tariffs, and ...

AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality ...

Coronary artery disease continues to be a prime public health concern worldwide, representing a leading cause of morbidity and mortality. Despite remarkable ...

European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...

European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...